Quarter Period Consolidated Statement Of Comprehensive Income

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7557806

Concept 2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
Quarter period consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
591,000,000 JPY
591,000,000 JPY
591,000,000 JPY
591,000,000 JPY
4,238,000,000 JPY
682,000,000 JPY
682,000,000 JPY
682,000,000 JPY
4,290,000,000 JPY
682,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
1,371,000,000 JPY
406,000,000 JPY
Remeasurements of defined benefit plans, net of tax
144,000,000 JPY
121,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
229,000,000 JPY
164,000,000 JPY
Other comprehensive income
1,745,000,000 JPY
692,000,000 JPY
Comprehensive income
5,983,000,000 JPY
4,982,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
5,983,000,000 JPY
4,982,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.